title: [Relationship between effectiveness of hepatic artery injection chemotherapy and serum VEGF].
abstract: Elevated plasma VEGF levels were reported in patients with colorectal cancer. This report presents regarding VEGF in patients who underwent hepatic artery injection chemotherapy (TAI) for liver metastasis of colorectal cancers. Thirty patients who underwent TAI for liver metastases of colorectal cancer during January 2002 to March 2003 were studied. Their serum CEA, CA19-9, and plasma VEGF were measured, and the relationships between these, their doubling times (DT) and therapeutic efficacy were examined. While the detected values and DTs were not considered significant, the tendency for DT to be the same was observed. One case with negative CEA and CA19-9 had high VEGF but negative VEGF-DT, which is compatible with therapeutic effects (PR). It appears that VEGF is a parameter that changes without direct correlation to CEA or CA19-9, and that VEGF may possibly be used as a therapeutic marker for cases with negative CEA or CA19-9.
authors: Dept. of Surgery, Saitama Medical Center, Saitama Medical School.
authors: Norimichi
authors: N
authors: Okada
authors: Hideyuki
authors: H
authors: Ishida
authors: Ikuya
authors: I
authors: Takeuchi
authors: Masaru
authors: M
authors: Yokoyama
authors: Hiroshi
authors: H
authors: Nakata
authors: Daijo
authors: D
authors: Hashimoto
authors: Yoshiro
authors: Y
authors: Matsumoto
authors: Tsuyoshi
authors: T
authors: Miura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000097:blood* / Q000556:secondary / Q000628:therapy*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D013213:Starch / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D042461:Vascular Endothelial Growth Factor A; C083286:degradable starch microspheres; D016685:Mitomycin; D007459:Iodized Oil; D004317:Doxorubicin; D013213:Starch; D005472:Fluorouracil